Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Sep 29, 2026
B. Riley Financial (RILY): Can It Reclaim the $10 Level?

B. Riley Financial (RILY): Can It Reclaim the $10 Level?

Key Takeaways

  • The central question is whether B. Riley Financial, Inc. (NASDAQ: RILY) can reclaim the widely watched $10 psychological level after trading near roughly $5.50 in recent sessions.
  • The strongest bullish case rests on the stock's recent history: it traded above $11 within the past year, meaning $10 is not an abstract aspiration but a level the shares have already visited.
  • The biggest obstacles are a strained balance sheet, negative stockholder equity, elevated leverage, and extremely thin, mostly bearish sell-side coverage.
  • Key technical markers include the 52-week low near $3.64 as support, with $8 and the $10–$11 zone acting as the principal resistance overhead.
  • The practical takeaway: reaching $10 would require a material improvement in financial health and sentiment, not simply a short-term bounce.

Why the $10 Level Draws Attention

B. Riley Financial is a diversified financial services company spanning investment banking, capital markets, wealth management, financial consulting, and asset-disposition services. After a turbulent stretch marked by declining revenues, regulatory scrutiny, and questions about its capital structure, the firm has restructured and rebranded as BRC Group Holdings while retaining the RILY ticker.

The $10 price objective carries meaning for two reasons. First, it is a classic round-number psychological level that traders and algorithms often treat as a magnet and a resistance point. Second, the stock has traded well above this threshold within its 52-week range, which spans roughly $3.64 to $11.24. That recent history makes $10 feel attainable to investors who believe the company's worst problems are behind it, while the current price near $5.50 means the shares would still need to roughly double to get there.

Where RILY Stands Today

In late September 2026, RILY traded near $5.49, giving the company a market capitalization of roughly $220 million. The stock's price-to-earnings ratio appears deceptively low at under 1x, but that figure reflects large non-recurring items flowing through reported earnings per share rather than sustainable profitability, so it should not be read as evidence of genuine cheapness. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

More telling are the balance-sheet metrics. The company has reported negative stockholder equity, meaning liabilities exceed the book value of assets, alongside a very high debt-to-equity ratio. These conditions are typically associated with distressed or heavily recapitalized companies, and they explain why the market continues to assign the stock a substantial risk discount even after its rebranding.

Factors That Could Push RILY Higher

Several factors would need to align for RILY to mount a sustained move toward $10. A return to consistent, cash-flow-positive operations across its core businesses would be the single most important catalyst. Successful completion of its restructuring, including meaningful debt reduction or a materially improved liquidity position, would directly address the market's largest concern about the company's viability.

On the technical side, the stock's prior presence above $11 demonstrates that buyers were willing to pay those prices relatively recently. A decisive push back above the $8 area, followed by a retest of the $10–$11 band, would signal a shift in the supply-demand balance. Historically, shares that reclaim former trading zones after a deep drawdown can move quickly because there is limited overhead supply until the next major distribution area.

Hurdles Standing in the Way

The obstacles are substantial. Negative book value and heavy leverage leave limited margin for error if revenues weaken or capital markets activity slows. The company has already suspended its common dividend, removing one traditional reason income-oriented investors might accumulate shares. Insider activity has also leaned toward selling in recent reporting periods, which does not suggest management is aggressively signaling confidence through open-market purchases.

Perhaps most notably, the limited Wall Street coverage that exists leans bearish. Independent ratings tracked by data providers point to a consensus "Sell" stance, with very few firms publishing constructive twelve-month price targets. That thin, cautious coverage limits the kind of incremental upgrades that often fuel multi-bagger recoveries in distressed financial names.

What Analysts Are Saying

Analyst price targets for RILY are scarce and, where published, conservative relative to the $10 objective. Some tracked data points to a lone reiterated target near the $10 mark, but broader consensus frameworks rank the stock as a sell, reflecting low visibility into a durable earnings recovery. The absence of meaningful positive revisions means the stock currently lacks the institutional endorsement that typically precedes a sustained re-rating.

Independent valuation models have occasionally produced far higher intrinsic-value estimates, but these outputs depend heavily on assumptions about normalized cash flow that the market has repeatedly rejected in practice. For the $10 target to become consensus, analysts would need to see concrete evidence of de-leveraging and recurring profitability, not just model-based upside.

Key Technical Levels to Watch

From a technical-analysis perspective, the $3.64 52-week low represents the key support level investors should watch; a break below it would signal renewed downside pressure and undermine any near-term recovery thesis. To the upside, $8 is the first meaningful resistance zone, followed by the psychologically significant $10 level and the 52-week high near $11.24. A sustained move toward $10 would likely require first clearing and holding above $8, confirming that buyers are absorbing supply rather than triggering only brief short-covering rallies. One thing that stands out here is how the stock has behaved around these zones in the past.

My Take on the Outlook

The prospect of RILY reaching $10 is best characterized as possible but far from assured. The stock has traded above that level within the past year, which keeps the target grounded in recent reality rather than pure speculation. However, the current price near $5.50 reflects genuine investor skepticism about the company's balance sheet, leverage, and earnings durability — concerns that a rebranding alone cannot resolve.

The strongest arguments in favor of the move are the stock's history above $11 and the potential for a successful turnaround if restructuring efforts restore consistent profitability and reduce debt. The primary risks are negative stockholder equity, heavy leverage, a suspended dividend, and thin, bearish analyst coverage. Going forward, investors should monitor liquidity and debt levels, any return to positive recurring earnings, insider transaction patterns, and the stock's ability to hold above key support near $3.64 while challenging resistance near $8. None of this constitutes a forecast; the path to $10 depends on fundamental improvement the market has not yet been willing to price in.

Monitoring Signals with AI Tools

In my own process for tracking names like this, I frequently review Tickeron's AI Daily Buy/Sell Signals. The platform applies artificial intelligence to scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals based on technical behavior and market conditions. It offers a practical way to stay objective when assessing whether momentum is building or fading.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RILY
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an independent investment bank

Industry FinancialConglomerates

Industry
Investment Banks Or Brokers
Address
11100 Santa Monica Boulevard
Phone
+1 310 966-1444
Employees
1552
Web
https://www.brcgh.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.